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progenitor cells. The aim of this study is to determinate the useful of
the hAMSC and the hAEC on regenerating human joint cartilage in an in
vitro model.
Methods: HAM was used as support for the culture of hAMSCs or hAECs.
Focal injuries in human joint cartilage biopsies were done. Later, a pellet
of cells (hAMSCs or hAECs, depending on the repair model developed)
was implanted into the focal defects of cartilage. HAM, with the cells
grown on it, was placed in direct contact with the cartilage surface to be
repaired. These implants were cultured in DMEM+10% FBS for 8 weeks.
The repair tissues were analyzed by histological and histochemistry
analysis considering the ICRS macroscopic evaluation of cartilage repair.
Results: hAMSCs and hAECs cultured on HAM and transplanted onto
focal injuries of cartilage penetrated into the nearby surface of the
chondral defect. The Hematoxylin and Eosin staining showed that
hAMSC or hAECs pellet ﬁlled the chondral defect. There was a good
integration between the repair tissue and native cartilage. Type II
collagen and aggrecan stainings of repair tissue were slightly positive on
the extracellular matrix, and positive inside the cytoplasm of the cells.
The safranin O staining expressed the presence of proteoglycans. Finally,
type I collagen stainings were weak or totally negative (Figure 1A). We
realized an ICRS macroscopic evaluation of cartilage repair to compare
both kinds of progenitor cells in the in vitro model. hAMSCs displayed
better degree of defect repair, greatest integration to border zone and,
in general, higher repair assessment (Figure 1B).
Conclusions: We get reduce the area of the defect with quality
integration. The morphology of the repair tissue showed a
ﬁbrocartilaginous appearance and a high cellularity. hAMSCs showed
better results considering the ICRS macroscopic evaluation of cartilage
repair.
Fig. 1. (A) Histological and histochemistry analysis of hAMSCs and hAECs
in vitro models; (B) Table with hAMSCs and hAECs means assessment
considering the ICRS macroscopic evaluation of cartilage repair.
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Purpose: In vitro differentiation of mesenchymal stem cells (MSC) for
osteo-articular tissue engineering involves speciﬁc differentiation factors
like cytokines and growth factors. Moreover, scaffolds are often used,
principally hydrogels, to culture MSC. In this work we studied the
inﬂuence of the hydrogel composition on MSC differentiation without
using speciﬁc differentiation factors.
Methods: Hydrogels were prepared by mixing rat tail type I collagen
(ColI), hydroxyapatite (Hap) microparticles at different sizes (150mm-
large, 80mm-medium and 30mm-small) and bone marrowMSCs to obtain
a ﬁnal concentration of 3mg/ml colI; 1mg/ml, 2mg/ml or 3mg/ml of Hap
and 5.105 cell/ml. pH was adjusted to 7 and the mixture was distributed
on each well of 96-well culture plates. Gels without Hap were used
as controls. The behavior of MSC over 21 days of culture was studied:
viability by confocal microscopy, gel contraction, cell metabolism, cell
proliferation and transcription factors speciﬁc of different differentiation
pathways (Sox-9 for chondrogenesis, Runx-2 for osteogenesis, PPAR-g for
adipogenesis) by PCR.
Results: Images obtained by confocal microscopy showed that type I
collagen/hydroxyapatite hydrogels are biocompatible with the MSC. For
all the conditions essayed, there were few dead cells, all over the culture
period. Moreover, we observed that the behavior of the cells follows an
evolution in two phases: the ﬁrst, until 14 days in culture supports the
cellular proliferation and the contraction of the gel while the second
period, from day 14 to day 21, involves a cellular commitment of the
cells in differentiation pathways. While Hap concentration or particle size
inside gels did not inﬂuence cell viability or proliferation, its presence
inﬂuences cell differentiation. The gene expression analysis shows a
signiﬁcant increase of the chondrogenic transcription factor Sox-9 for
the cells culture on gels containing Hap. Moreover, differences were
found according to particle size or concentration.
Conclusions: The results suggest that MSC differentiation can be
modulated by hydrogels composition. That will be useful for tissue
engineering because to avoid the use of cytokines or growth factors
could facilitate therapeutic applications.
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EFFECTS OF ORAL ADMINISTRATION OF HYAL-JOINT® FOR THE
TREATMENT OF KNEE OSTEOARTHRITIS WITH SYNOVIAL EFFUSION:
A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY
I. Mo¨ller1, D. Martinez-Puig2, C. Chetrit2. 1Inst. Poal de Reumatologia,
Barcelona, Spain; 2BIOIBERICA S.A., Palafolls, Spain
Purpose: To evaluate the clinical efﬁcacy of (Hyal-Joint®) in patients with
moderate to severe osteoarthritis of the knee coursing with persistent
knee pain and joint effusion.
Methods: 70 adults with moderate to severe knee OA (grades II-III
of K-L criteria) and presenting lateral or longitudinal synovial effusion
(>4mm at the suprapatellar recess) were recruited between March and
August 2010 in a prospective, double-blind, placebo-controlled trial with
a parallel design. Patients were randomly assigned to receive either Hyal-
Joint® (Bioiberica, Palafolls, Spain; n = 35) or Placebo (PCT; n =35) at a
dose of 80mg/d during a period of 3 months. The primary outcome was
the course of synovial effusion assessed monthly in the suprapatellar
recess using ultrasonography (US) equipment with a high frequency
linear array. The maximal synovial thickness and effusion depth were
measured in mm using the longitudinal scale according to a standard
published protocol. The secondary outcome was the pain intensity
assessed weekly using the Huskisson’s visual analogue scale (VAS).
Results: At baseline the mean synovial effusion was similar between
treatment groups (6.85 and 6.16mm for Hyal-Joint® and placebo groups
respectively). Synovial effusion was progressively reduced in both groups
during the experimental period, reaching a lower value in the Hyal-
Joint® group (2.72mm) in comparison with the placebo group (3.15mm)
at 3 months. Pain intensity was also similar between groups at baseline
(6.4 and 6.5 cm for for Hyal-Joint® and placebo groups respectively).
Pain perception was progressively reduced from baseline until the end
of the trial in both groups. From week 9 until week 12 pain reduction
was more pronounced in group Hyal-Joint® group in comparison with
placebo. In the Hyal-Joint® group, at week 9, pain intensity was 50%
reduced from basal values, while the reduction was only of 32% for
the placebo group. Differences between treatment groups in both pain
intensity and synovial effusion were clinically relevant and tended to
reach statistical signiﬁcance.
Conclusions: Our results suggest that the use of Hyal-Joint® for the
management of the knee osteoarthritis coursing with synovial effusion
is safe and well tolerated, tending to show clinical beneﬁts in pain
remission and helping to control synovial inﬂammation.
